These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26797241)

  • 1. The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?
    Kircher SM; Meeker CR; Nimeiri H; Geynisman DM; Zafar SY; Shankaran V; de Souza J; Wong YN
    Value Health; 2016 Jan; 19(1):88-98. PubMed ID: 26797241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
    Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
    JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group health plans and health insurance issuers relating to coverage of preventive services under the Patient Protection and Affordable Care Act. Final rules.
    ; ;
    Fed Regist; 2012 Feb; 77(31):8725-30. PubMed ID: 22379684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shared responsibility payment for not maintaining minimum essential coverage. Final regulations.
    Internal Revenue Services (IRS), Treasury
    Fed Regist; 2013 Aug; 78(169):53646-64. PubMed ID: 23991478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral oncolytics: Part 2--legislation targeting cost & access, and other initiatives to reduce costs.
    Mancini R; McBride A; Kruczynski M
    Oncology (Williston Park); 2013 Sep; 27(9):865-6, 871. PubMed ID: 24282981
    [No Abstract]   [Full Text] [Related]  

  • 6. Minimum essential coverage and other rules regarding the shared responsibility payment for individuals. Final regulations.
    Internal Revenue Service (IRS), Treasury
    Fed Regist; 2014 Nov; 79(228):70464-70. PubMed ID: 25427342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient Protection and Affordable Care Act; HHS notice of benefit and payment parameters for 2015. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2014 Mar; 79(47):13743-843. PubMed ID: 24693562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2017. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2016 Mar; 81(45):12203-352. PubMed ID: 26964153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.
    Chin AL; Bentley JP; Pollom EL
    Cancer; 2019 Feb; 125(3):374-381. PubMed ID: 30566762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
    Spargo A; Yost C; Squires P; Raju A; Schroader B; Brown JD
    J Manag Care Spec Pharm; 2021 May; 27(5):554-564. PubMed ID: 33908275
    [No Abstract]   [Full Text] [Related]  

  • 11. Final Rules for Grandfathered Plans, Preexisting Condition Exclusions, Lifetime and Annual Limits, Rescissions, Dependent Coverage, Appeals, and Patient Protections Under the Affordable Care Act. Final rules.
    ; ;
    Fed Regist; 2015 Nov; 80(222):72191-294. PubMed ID: 26595941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Legal Setback for the Affordable Care Act.
    Bagley N
    N Engl J Med; 2016 Jun; 374(24):2307-9. PubMed ID: 27248445
    [No Abstract]   [Full Text] [Related]  

  • 14. Mitigating the effects of churning under the Affordable Care Act: lessons from Medicaid.
    Rosenbaum S; Lopez N; Dorley M; Teitelbaum J; Burke T; Miller J
    Issue Brief (Commonw Fund); 2014 Jun; 12():1-8. PubMed ID: 24988615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Will the Affordable Care Act's Cost-Sharing Reductions Affect Consumers' Out-of-Pocket Costs in 2016?
    Collins SR; Gunja M; Beutel S
    Issue Brief (Commonw Fund); 2016 Mar; 6():1-17. PubMed ID: 27017638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic health program: state administration of basic health programs; eligibility and enrollment in standard health plans; essential health benefits in standard health plans; performance standards for basic health programs; premium and cost sharing for basic health programs; federal funding process; trust fund and financial integrity. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2014 Mar; 79(48):14111-51. PubMed ID: 24693564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health insurance reform legislation.
    DiSimone RL
    Soc Secur Bull; 1997; 60(4):18-31. PubMed ID: 9483710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSR Cuts Bring Unintended Consequences, Prompt State Responses.
    Kirkner RM
    Manag Care; 2017 Dec; 26(12):12-13. PubMed ID: 29272230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mental health parity legislation, cost-sharing and substance-abuse treatment admissions.
    Dave D; Mukerjee S
    Health Econ; 2011 Feb; 20(2):161-83. PubMed ID: 20029912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The House and the ACA--A Lawsuit over Cost-Sharing Reductions.
    Jost TS
    N Engl J Med; 2016 Jan; 374(1):5-7. PubMed ID: 26536301
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.